|
1
|
Berwick M, Erdei E and Hay J: Melanoma
epidemiology and public health. Dermatol Clin. 27:205–214. 2009.
View Article : Google Scholar
|
|
2
|
Becker D, Mihm MC, Hewitt SM, Sondak VK,
Fountain JW and Thurin M: Markers and tissue resources for
melanoma: meeting report. Cancer Res. 66:10652–10657.
2006.PubMed/NCBI
|
|
3
|
Nazarian RM, Prieto VG, Elder DE and
Duncan LM: Melanoma biomarker expression in melanocytic tumor
progression: a tissue microarray study. J Cutan Pathol. 37:41–47.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lacal PM, Failla CM, Pagani E, et al:
Human melanoma cells secrete and respond to placenta growth factor
and vascular endothelial growth factor. J Invest Dermatol.
115:1000–1007. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lacal PM, Ruffini F, Pagani E and D’Atri
S: An autocrine loop directed by the vascular endothelial growth
factor promotes invasiveness of human melanoma cells. Int J Oncol.
27:1625–1632. 2005.PubMed/NCBI
|
|
6
|
Schietroma C, Cianfarani F, Lacal PM, et
al: Vascular endothelial growth factor-C expression correlates with
lymph node localization of human melanoma metastases. Cancer.
98:789–797. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ruffini F, Failla CM, Orecchia A, et al:
Expression of the soluble vascular endothelial growth factor
receptor-1 in cutaneous melanoma: role in tumour progression. Br J
Dermatol. 164:1061–1070. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hennequin LF, Thomas AP, Johnstone C, et
al: Design and structure-activity relationship of a new class of
potent VEGF receptor tyrosine kinase inhibitors. J Med Chem.
42:5369–5389. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sasaki T, Kishi M, Saito M, et al:
Inhibitory effect of di- and tripeptidyl aldehydes on calpains and
cathepsins. J Enzyme Inhib. 3:195–201. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lacal PM, Morea V, Ruffini F, et al:
Inhibition of endothelial cell migration and angiogenesis by a
vascular endothelial growth factor receptor-1 derived peptide. Eur
J Cancer. 44:1914–1921. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lacal PM, Tentori L, Muzi A, et al:
Pharmacological inhibition of poly(ADP-ribose) polymerase activity
down-regulates the expression of syndecan-4 and Id-1 in endothelial
cells. Int J Oncol. 34:861–872. 2009.PubMed/NCBI
|
|
12
|
Ruffini F, D’Atri S and Lacal PM:
Neuropilin-1 expression promotes invasiveness of melanoma cells
through vascular endothelial growth factor receptor-2 dependent and
independent mechanisms. Int J Oncol. 43:297–306. 2013.
|
|
13
|
Stetler-Stevenson WG: Matrix
metalloproteinases in angiogenesis: a moving target for therapeutic
intervention. J Clin Invest. 103:1237–1241. 1999.PubMed/NCBI
|
|
14
|
Wang Z, Juttermann R and Soloway PD:
TIMP-2 is required for efficient activation of proMMP-2 in vivo. J
Biol Chem. 275:26411–26415. 2000. View Article : Google Scholar
|
|
15
|
Hoek KS, Schlegel NC, Eichhoff OM, et al:
Novel MITF targets identified using a two-step DNA microarray
strategy. Pigment Cell Melanoma Res. 21:665–676. 2008. View Article : Google Scholar
|
|
16
|
Fredriksson L, Ehnman M, Fieber C and
Eriksson U: Structural requirements for activation of latent
platelet-derived growth factor CC by tissue plasminogen activator.
J Biol Chem. 280:26856–26862. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X, Pontén A, Aase K, et al: PDGF-C is a
new protease-activated ligand for the PDGF alpha-receptor. Nat Cell
Biol. 2:302–309. 2000. View
Article : Google Scholar
|
|
18
|
Gilbertson DG, Duff ME, West JW, et al:
Platelet-derived growth factor C (PDGF-C), a novel growth factor
that binds to PDGF alpha and beta receptor. J Biol Chem.
276:27406–27414. 2001.PubMed/NCBI
|
|
19
|
Fredriksson L, Li H, Fieber C, Li X and
Eriksson U: Tissue plasminogen activator is a potent activator of
PDGF-CC. EMBO J. 23:3793–3802. 2004.
|
|
20
|
Cao R, Bråkenhielm E, Li X, et al:
Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF
family, involves activation of PDGFR-αα and -αβ receptors. FASEB J.
16:1575–1583. 2002.PubMed/NCBI
|
|
21
|
Dimmeler S: Platelet-derived growth factor
CC - a clinically useful angiogenic factor at last? N Engl J Med.
352:1815–1816. 2005.PubMed/NCBI
|
|
22
|
Li X, Tjwa M, Moons L, et al:
Revascularization of ischemic tissues by PDGF-CC via effects on
endothelial cells and their progenitors. J Clin Invest.
115:118–127. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Anderberg C, Li H, Fredriksson L, et al:
Paracrine signaling by platelet-derived growth factor-CC promotes
tumor growth by recruitment of cancer associated fibroblasts.
Cancer Res. 69:369–378. 2009.PubMed/NCBI
|
|
24
|
Hurst NJ Jr, Najy AJ, Ustach CV, Movilla L
and Kim HR: Platelet-derived growth factor-C (PDGF-C) activation by
serine proteases: implications for breast cancer progression.
Biochem J. 441:909–918. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zwerner JP and May WA: PDGF-C is an
EWS/FLI induced transforming growth factor in Ewing family tumors.
Oncogene. 20:626–633. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zwerner JP and May WA: Dominant negative
PDGF-C inhibits growth of Ewing family tumor cell lines. Oncogene.
21:3847–3854. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Andrae J, Molander C, Smits A, Funa K and
Nistér M: Platelet-derived growth factor-B and -C and active
alpha-receptors in medulloblastoma cells. Biochem Biophys Res
Commun. 296:604–611. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lokker NA, Sullivan CM, Hollenbach SJ,
Israel MA and Giese NA: Platelet-derived growth factor (PDGF)
autocrine signaling regulates survival and mitogenic pathways in
glioblastoma cells: evidence that the novel PDGF-C and PDGF-D
ligands may play a role in the development of brain tumours. Cancer
Res. 62:3729–3735. 2002.
|
|
29
|
Yamano Y, Uzawa K, Saito K, et al:
Identification of cisplatin-resistance related genes in head and
neck squamous cell carcinoma. Int J Cancer. 126:437–449. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Crawford Y, Kasman I, Yu L, et al: PDGF-C
mediates the angiogenic and tumorigenic properties of fibroblasts
associated with tumors refractory to anti-VEGF treatment. Cancer
Cell. 15:21–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li X, Kumar A, Zhang F, Lee C, Li Y, Tang
Z and Arjuna P: VEGF-independent angiogenic pathways induced by
PDGF-C. Oncotarget. 1:309–314. 2010.PubMed/NCBI
|
|
32
|
di Tomaso E, London N, Fuja D, et al:
PDGF-C induces maturation of blood vessels in a model of
glioblastoma and attenuates the response to anti-VEGF treatment.
PLoS One. 4:e51232009.PubMed/NCBI
|
|
33
|
Ono Y, Ojima K, Torii F, et al: Skeletal
muscle-specific calpain is an intracellular
Na+-dependent protease. J Biol Chem. 285:22986–22998.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Storr SJ, Carragher NO, Frame MC, Parr T
and Martin SG: The calpain system and cancer. Nat Rev Cancer.
11:364–374. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Moretti D, Del Bello B, Cosci E, Biagioli
M, Miracco C and Maellaro E: Novel variants of muscle calpain 3
identified in human melanoma cells: cisplatin-induced changes in
vitro and differential expression in melanocytic lesions.
Carcinogenesis. 30:960–967. 2009. View Article : Google Scholar
|
|
36
|
Hodgkinson CA, Moore KJ, Nakayama A,
Steingrímsson E, Copeland NG, Jenkins NA and Arnheiter H: Mutations
at the mouse microphthalmia locus are associated with defects in a
gene encoding a novel basic-helix-loop-helix-zipper protein. Cell.
74:395–404. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vachtenheim J, Novotna H and Ghanem G:
Transcriptional repression of the microphthalmia gene in melanoma
cells correlates with the unresponsiveness of target genes to
ectopic microphthalmia-associated transcription factor. J Invest
Dermatol. 117:1505–1511. 2001. View Article : Google Scholar
|
|
38
|
McGill GG, Horstmann M, Widlund HR, et al:
Bcl2 regulation by the melanocyte master regulator Mitf modulates
lineage survival and melanoma cell viability. Cell. 109:707–718.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Du J, Widlund HR, Horstmann MA, et al:
Critical role of CDK2 for melanoma growth linked to its
melanocyte-specific transcriptional regulation by MITF. Cancer
Cell. 6:565–576. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Steingrimsson E, Copeland NG and Jenkins
NA: Melanocytes and the microphthalmia transcription factor
network. Annu Rev Genet. 38:365–411. 2004. View Article : Google Scholar
|
|
41
|
Carreira S, Goodall J, Aksan I, et al:
Mitf cooperates with Rb1 and activates p21Cip1
expression to regulate cell cycle progression. Nature. 433:764–769.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Loercher AE, Tank EM, Delston RB and
Harbour JW: MITF links differentiation with cell cycle arrest in
melanocytes by transcriptional activation of INK4A. J Cell Biol.
168:35–40. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Levy C, Khaled M and Fisher DE: MITF:
master regulator of melanocyte development and melanoma oncogene.
Trends Mol Med. 12:406–414. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu M, Hemesath TJ, Takemoto CM, et al:
c-Kit triggers dual phosphorylations, which couple activation and
degradation of the essential melanocyte factor Mi. Genes Dev.
14:301–312. 2000.PubMed/NCBI
|
|
45
|
Levy C, Sonnenblick A and Razin E: Role
played by microphthalmia transcription factor phosphorylation and
its Zip domain in its transcriptional inhibition by PIAS3. Mol Cell
Biol. 23:9073–9080. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
De Morrée A, Hulsik DL, Impagliazzo A, et
al: Calpain 3 is a rapid-action, unidirectional proteolytic switch
central to muscle remodelling. PLoS One. 5:e119402010.PubMed/NCBI
|
